Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease

被引:238
作者
Boulman, N
Levy, Y
Leiba, R
Shachar, S
Linn, R
Zinder, O
Blumenfeld, Z
机构
[1] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Obstet & Gynecol, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Internal Med, IL-31096 Haifa, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Clin Biochem, IL-31096 Haifa, Israel
[4] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Stat Unit, IL-31096 Haifa, Israel
[5] Inst Technol & Meuhedet Med Serv, IL-31096 Haifa, Israel
关键词
D O I
10.1210/jc.2003-031096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The polycystic ovary syndrome ( PCOS), one of the most common reproductive abnormalities, shares some components of the metabolic cardiovascular syndrome. Therefore, PCOS patients may represent the largest group of women at high risk for the development of early-onset cardiovascular disease (CVD) and/or diabetes. C-reactive protein (CRP) is a strong independent predictor of future CVD and/or stroke. Only one small published study has looked for such an association (17 PCOS patients vs. 15 controls). The objective of this study was to compare the levels of CRP and other risk factors of CVD in a large group of PCOS patients and controls. CRP measurements were undertaken in 116 PCOS patients and 94 body mass index-matched controls with regular menstrual cycles. Whereas 36.8% of the PCOS patients had CRP levels above 5 mg/liter, only 9.6% of the controls exhibited high CRP levels (P < 0.001). The mean +/- SD was 5.46 +/- 7.0 in the PCOS group vs. 2.04 +/- 1.9 mg/liter in the control (P < 0.001). The body mass index, white blood cell count, TSH, glucose, cholesterol, and homocysteine levels were not significantly different between the two groups. CRP levels are elevated in patients with PCOS and may be a marker of early cardiovascular risk in these patients. High CRP levels may explain why some PCOS women may possibly be at an increased risk for the development of early-onset CVD. Consequently, whether treatment regimens directed toward lowering CVD risk factors should be more aggressive for those PCOS women with increased CRP levels, awaits further clinical experience.
引用
收藏
页码:2160 / 2165
页数:6
相关论文
共 34 条
  • [11] Urinary sex hormone excretions in premenopausal women and coronary heart disease risk: A nested case-referent study in the DOM-cohort
    Gorgels, WJMJ
    vanderGraaf, Y
    Blankenstein, MA
    Collette, HJA
    Erkelens, DW
    Banga, JD
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (03) : 275 - 281
  • [12] Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study
    Guzick, DS
    Talbott, EO
    SuttonTyrrell, K
    Herzog, HC
    Kuller, LH
    Wolfson, SK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (04) : 1224 - 1229
  • [13] Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome
    Harborne, L
    Fleming, R
    Lyall, H
    Norman, J
    Sattar, N
    [J]. LANCET, 2003, 361 (9372) : 1894 - 1901
  • [14] Low grade chronic inflammation in women with polycystic ovarian syndrome
    Kelly, CCJ
    Lyall, H
    Petrie, JR
    Gould, GW
    Connell, JMC
    Sattar, N
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06) : 2453 - 2455
  • [15] Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
    Knochenhauer, ES
    Key, TJ
    Kahsar-Miller, M
    Waggoner, W
    Boots, LR
    Azziz, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) : 3078 - 3082
  • [16] Polycystic ovary syndrome and cardiovascular disease: A premature association?
    Legro, RS
    [J]. ENDOCRINE REVIEWS, 2003, 24 (03) : 302 - 312
  • [17] Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome
    Morin-Papunen, L
    Rautio, K
    Ruokonen, A
    Hedberg, P
    Puukka, M
    Tapanainen, JS
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) : 4649 - 4654
  • [18] MORINPAPUENEN L, 2000, HUM FERTIL, V3, P101
  • [19] PASSING H, 1983, J CLIN CHEM CLIN BIO, V21, P709
  • [20] Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association
    Pearson, TA
    Mensah, GA
    Alexander, RW
    Anderson, JL
    Cannon, RO
    Criqui, M
    Fadl, YY
    Fortmann, SP
    Hong, Y
    Myers, GL
    Rifai, N
    Smith, SC
    Taubert, K
    Tracy, RP
    Vinicor, F
    [J]. CIRCULATION, 2003, 107 (03) : 499 - 511